Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKN24011 in Moderate to Severe COPD
NCT07440524Phase 2Completed
- Sponsor
- Joincare Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JKN24011 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Joincare Pharmaceutical. Primary endpoint: Annualised rate of moderate or severe COPD exacerbations at 52 weeks. Started Aug 2024; status: completed.
02
Drugs
JKN24011
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07440524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440524.